 NEW YORK and SAN DIEGO, Feb. 24, 2021 GLOBE NEWSWIRE -- Zentalis Pharmaceuticals, Inc. Nasdaq: ZNTL, a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that initial clinical data from the Phase 1 portion of its Phase 12 monotherapy trial of ZN-c3, the Companys WEE1 inhibitor, in advanced solid tumors has been selected for presentation at the upcoming virtual American Association for Cancer Research AACR Annual Meeting 2021. AACR is being held April 10-15 and May 17-21. 